Voyager Therapeutics (FRA:VT6) EV-to-EBIT : -5.95 (As of Jun. 09, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Voyager Therapeutics's Enterprise Value is €97.7 Mil. Voyager Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-16.4 Mil. Therefore, Voyager Therapeutics's EV-to-EBIT for today is -5.95.

The historical rank and industry rank for Voyager Therapeutics's EV-to-EBIT or its related term are showing as below:

FRA:VT6' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.84 Med: -3.15 Max: 8.69
Current: -6.24

During the past 11 years, the highest EV-to-EBIT of Voyager Therapeutics was 8.69. The lowest was -45.84. And the median was -3.15.

FRA:VT6's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.8 vs FRA:VT6: -6.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Voyager Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was €149.1 Mil. Voyager Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-16.4 Mil. Voyager Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -11.02%.

Voyager Therapeutics EV-to-EBIT Historical Data

The historical data trend for Voyager Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics EV-to-EBIT Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-5.16

4.88

-0.20

-2.75

1.32

Voyager Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															0.90	2.86	2.50	1.32	-9.03

Competitive Comparison of Voyager Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Voyager Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's EV-to-EBIT falls into.

Voyager Therapeutics EV-to-EBIT Calculation

Voyager Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	97.678	/	-16.428
	=	-5.95

Voyager Therapeutics's current Enterprise Value is €97.7 Mil.
Voyager Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.4 Mil.

Voyager Therapeutics (FRA:VT6) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Voyager Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-16.428	/	149.06447
	=	-11.02 %

Voyager Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was €149.1 Mil.
Voyager Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.4 Mil.

Voyager Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (FRA:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (FRA:VT6) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (FRA:VT6) Headlines

No Headlines